Cardiorentis is a privately owned biopharmaceutical company designed for the new world of drug development
AHF can be defined as the sudden or gradual onset of the signs or symptoms of heart failure resulting in a need for urgent therapy or hospitalisation.
Ularitide is an advanced natriuretic peptide in Phase III development as an intravenous (IV) infusion treatment for acute heart failure (AHF).
Cardiorentis AG is a privately owned pharmaceutical company based in Zug, Switzerland.
Focused, fast moving, flexible, with patients at its heart, Cardiorentis
is committed to introducing the first therapy with proven outcome
benefits for patients with acute heart failure and developing innovative
medicines for diseases of high unmet medical need.
Financing with HealthCare Royalty Partners to Fund Ularitide Registration Program in Acute Heart Failure
At Acute Cardiovascular Care 2014 (ACC2014) 18th – 20th October 2014 in Geneva.
Visit our Stand E200 to find out the latest on the TRUE-AHF trial.